Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: A nationwide case-control study

Journal of Clinical Psychiatry

Volumn 74, Issue 1, 2013, Pages

  Yang, Shu Yu ^a,f   Liao, Ya Tang ^b,e   Liu, Hsing Cheng ^a,c   Chen, Wei J ^b   Chen, Chiao Chicy ^a,c,d   Kuo, Chian Jue ^a,b,c  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; CASE CONTROL STUDY; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG RESPONSE; DRUG USE; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TAIWAN; TREATMENT DURATION; VALIDATION PROCESS;

EID: 84873801056     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m07938     Document Type: Article

References (39)

1. Muller-Oerlinghausen B, Berghofer A, Bauer M. Bipolar disorder. Lancet. 2002;359(9302):241-247.
2. Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord 2011;13(4):pii: PCC.10r01097.
3. Nivoli AM, Murru A, Goikolea JM, et al. New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord. 2012;140(2): 125-141.
4. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306-1315.
5. Knol W, van Marum RJ, Jansen PA, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56(4):661-666.
6. Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152(7):418-425, W139-40.
7. Kuo CJ, Yang SY, Liao YT, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia [published online ahead of print Jan 26, 2012]. Schizophr Bull.
8. Wang PW, Hill SJ, Childers ME, et al. Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. J Psychiatr Res. 2011;45(8):1128-1132.
9. McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721-728.
10. Geddes JR, Goodwin GM, Rendell J, et al; BALANCE investigators and collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385-395.
11. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry. 1998;155(1):12-21.
12. Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition-recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23: 346-388.
13. Gau SS, Chao PF, Lin YJ, et al. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. J Clin Psychopharmacol. 2008;28(5):509-517.
14. Gau SS, Chung CH, Gau CS. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. J Clin Psychopharmacol. 2008;28(3):271-278.
15. ATC/DDD Index 2012. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc-ddd-index/. Updated December 19, 2011.Accessed October 24, 2012.
16. WHO Collaborating Centre for Drug Statistic Methodology. ATC Index With DDDs. Oslo: WHO; 2009.
17. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
18. Quail JM, Lix LM, Osman BA, et al. Comparing comorbidity measures for predicting mortality and hospitalization in three population-based cohorts. BMC Health Serv Res. 2011;11(1):146.
19. Mehta AJ, Guidot DM. Alcohol abuse, the alveolar macrophage and pneumonia. Am J Med Sci. 2012;343(3):244-247.
20. Feinstein AR. Clinical Epidemiology: The Architecture of Clinical Research. Philadelphia, PA: WB Saunders; 1985.
21. Maddalena AS, Fox M, Hofmann M, et al. Esophageal dysfunction on psychotropic medication: a case report and literature review. Pharmacopsychiatry. 2004;37(3):134-138.
22. Hinkes R, Quesada TV, Currier MB, et al. Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea. J Clin Psychopharmacol. 1996;16(6):462-463.
23. Virani A, Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical Handbook of Psychotropic Drugs. 18th ed. Cambridge, MA: Hogrefe & Huber; 2009.
24. Yang SY, Kao Yang YH, Chong MY, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther. 2007;81(4):586-594.
25. Gerlach J, Behnke K, Heltberg J, et al. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br J Psychiatry. 1985;147(3):283-288.
26. .Ziaie Z, Kefalides NA. Lithium chloride restores host protein synthesis in herpes simplex virus-infected endothelial cells. Biochem Biophys Res Commun. 1989;160(3):1073-1078.
27. Li J, Yin J, Sui X, et al. Comparative analysis of the effect of glycyrrhizin diammonium and lithium chloride on infectious bronchitis virus infection in vitro. Avian Pathol. 2009;38(3):215-221.
28. Ren X, Meng F, Yin J, et al. Action mechanisms of lithium chloride on cell infection by transmissible gastroenteritis coronavirus. PLoS ONE. 2011;6(5):e18669.
29. .Wang H, Brown J, Martin M. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine. 2011;53(2):130-140.
30. .Sutton LP, Rushlow WJ. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Neuroscience. 2011;199:116-124.
31. Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v carbamazepine alone in treating manic episodes. Br J Psychiatry. 2008;192(2):135-143.
32. Costello LE, Suppes T. A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol. 1995;15(2):139-141.
33. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol. 1998;54(8):639-643.
34. de Leon J, Santoro V, D'Arrigo C, et al. Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012;8(3):311-334.
35. Diaz FJ, Santoro V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41(3):81-91.
36. de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):1059-1063.
37. Lavsa SM, Fabian TJ, Saul MI, et al. Influence of medications and diagnoses on fall risk in psychiatric inpatients. Am J Health Syst Pharm. 2010;67(15):1274-1280.
38. Siracuse JJ, Odell DD, Gondek SP, et al. Health care and socioeconomic impact of falls in the elderly. Am J Surg. 2012;203(3):335-338, discussion 338.
39. Chang YT, Kuo CJ, Chen WJ, et al. Risk factors associated with pneumonia among schizophrenia patients. Taipei City Med J. 2012;9:11-20.